Subscribe To
Down 30% in a month, is there more pain for chemocentryx stock?
The stock price of ChemoCentryx, a biopharmaceuticals company focused on orally-administered therapeutics to treat ...
February 1, 2022, 6:00 am
Down 30% in a month, is there more pain for chemocentryx stock?
The stock price of ChemoCentryx, a biopharmaceuticals company focused on orally-administered therapeutics to treat ...
February 1, 2022, 6:00 am
Down 30% in a month, is there more pain for chemocentryx stock?
The stock price of ChemoCentryx, a biopharmaceuticals company focused on orally-administered therapeutics to treat ...
February 1, 2022, 6:00 am
Down 57% in a month, is there more pain for tg therapeutics stock?
The stock price of TG Therapeutics (NASDAQ: TGTX), a commercial stage biopharmaceutical company focused on the development of novel treatments for B-c...
January 31, 2022, 5:00 am
Down 57% in a month, is there more pain for tg therapeutics stock?
The stock price of TG Therapeutics (NASDAQ: TGTX), a commercial stage biopharmaceutical company focused on the development of novel treatments for B-c...
January 31, 2022, 5:00 am
Down 57% in a month, is there more pain for tg therapeutics stock?
The stock price of TG Therapeutics (NASDAQ: TGTX), a commercial stage biopharmaceutical company focused on the development of novel treatments for B-c...
January 31, 2022, 5:00 am
Argenx to present at upcoming investor conferences
November 10, 2021 Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people ...
November 10, 2021, 1:00 am
Argenx to present at upcoming investor conferences
November 10, 2021 Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people ...
November 10, 2021, 1:00 am
Argenx to present at upcoming investor conferences
November 10, 2021 Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people ...
November 10, 2021, 1:00 am
Chemocentryx's stock jumps 80% after receiving fda approval for vasculitis drug
Shares of ChemoCentryx Inc. CCXI, +5.43% soared 80.3% in premarket trading on Friday after the company said that it had received approval from the Foo...
October 8, 2021, 8:24 am
Chemocentryx's stock jumps 80% after receiving fda approval for vasculitis drug
Shares of ChemoCentryx Inc. CCXI, +5.43% soared 80.3% in premarket trading on Friday after the company said that it had received approval from the Foo...
October 8, 2021, 8:24 am
Chemocentryx's stock jumps 80% after receiving fda approval for vasculitis drug
Shares of ChemoCentryx Inc. CCXI, +5.43% soared 80.3% in premarket trading on Friday after the company said that it had received approval from the Foo...
October 8, 2021, 8:24 am
Argenx to highlight potential first-in-class fcrn antagonist efgartigimod at upcoming neuromuscular meetings
Breda, the Netherlands – October 8 , 2021 – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of peop...
October 8, 2021, 1:00 am
Argenx to highlight potential first-in-class fcrn antagonist efgartigimod at upcoming neuromuscular meetings
Breda, the Netherlands – October 8 , 2021 – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of peop...
October 8, 2021, 1:00 am
Argenx to highlight potential first-in-class fcrn antagonist efgartigimod at upcoming neuromuscular meetings
Breda, the Netherlands – October 8 , 2021 – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of peop...
October 8, 2021, 1:00 am
Eledon pharmaceuticals announces presentation on at-1501 at the virtual 2021 northeast amyotrophic lateral sclerosis consortium
IRVINE, Calif., Oct. 07, 2021 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a clinical stage biopharmaceutical compa...
October 7, 2021, 7:51 am
Eledon pharmaceuticals announces presentation on at-1501 at the virtual 2021 northeast amyotrophic lateral sclerosis consortium
IRVINE, Calif., Oct. 07, 2021 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a clinical stage biopharmaceutical compa...
October 7, 2021, 7:51 am
Eledon pharmaceuticals announces presentation on at-1501 at the virtual 2021 northeast amyotrophic lateral sclerosis consortium
IRVINE, Calif., Oct. 07, 2021 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a clinical stage biopharmaceutical compa...
October 7, 2021, 7:51 am